Santen Pharmaceutical (China) Co Ltd, a branch of Japanese company Santen Pharmaceutical Co Ltd, resumed operations on Feb 10 and is carrying out its original production plans regardless of the impact of the COVID-19.

“The local authorities at different levels have offered us great help in getting anti-epidemic supplies and solving logistics problems so that we could fully resume our operations soon. We are now moving smoothly toward our monthly and annual production goals, and are planning to build a new manufacturing and R&D facility in SIP in the future,” said an executive from the company.

 

Suzhou Shengdiya Biomedicine Co Ltd, a drug maker, is striving hard to realize this year’s goal of producing about 600,000 pieces of Camrelizumab for Injection, a humanized anti-PD-1 monoclonal antibody that is applicable to treatment of patients with refractory hepatocellular carcinoma.